1. 59. 21 CFR § 1271.3(d) (2017); Grant, supra note 43, at 615, 624-625; NAS MRT Report, supra note 11, at 25-38, 99-100.
2. 2. Califf, R. and Nalubola, R. , “FDA's Science-based Approach to Genome Editing Products,” FDA, January 18, 2017, available at (last visited November 16, 2018).
3. 185. Id.
4. 15. Drabiak, K. , “Engineering Consensus in the Development of Genome Editing Policy,” Hasting Center Bioethics Forum, March 14, 2017, available at (last visited November 16, 2018).
5. 128. Knoepfler, supra note 36.